Radiomics-based Malnutrition for Cervical Cancer.

Inclusion Criteria: 1. Patients received pelvic lymphadenectomy and radical hysterectomy, and pathological diagnosis of CC; 2. Patients had stage IB1-IIA2 CC based on the 2014 FIGO staging system for cervical cancer; 3. Patients received postoperative RT/CRT within one week after admission at the ZJPPH; 4. Patients must have Eastern Cooperative Oncology Group performance status 0-2; 5. No treatments prior to radical surgery; 6. Normal marrow function and the blood tests must be collected within 7 days from enrollment with a hemoglobin of ≥ 80g/L (can be transfused with red blood cells pre-study), an white blood cell (WBC) counts of ≥ 3.0×109/L，a neutrophil count of ≥ 2.0×109/L, , a platelet count of ≥100×109/L, a total bilirubin (TBil) of ≤ 1.0 upper normal limitation (UNL), a creatinine (Cr) of ≤ 1.0 UNL, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤ 2.5 UNL, Alkaline phosphatase (AKP) ≤5.0 UNL. and no major electrocardiogram abnormalities. 7. Patient does not have a known allergy to platinum (cisplatin or carboplatin) or compounds of similar biologic composition. 8. Patients must be with good compliance and agree to accept nutritional therapy; 9. Informed consent signed. - Exclusion Criteria: 1. Poor image quality or visible artifacts around the L3 psoas; 2. Prior treatments of chemotherapy or irradiation; 3. Poor bone marrow, liver and kidney functions, which would make chemotherapy or radiotherapy intolerable; 4. Participating in other clinical trials; 5. Pregnancy, breast feeding, or not adopting birth control; 6. Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities; 7. The subject has had another active malignancy within the past five years; 8. Poor image quality or visible artifacts around the L3 psoas. -